A novel analytical development and validation of an rp-hplc assay method for the quantification of apalutamide in bulk and its marketed formulation
DOI:
https://doi.org/10.61096/ijpar.v10.iss2.2021.259-265Keywords:
Apalutamide, RP-HPLC, Validation, ICH Guidelines.Abstract
A simple, rapid, specific and accurate reverse phase high performance liquid chromatographic method has been developed for th e validated of Apalutamide in bulk as well as in marketed pharmaceutical dosage form. This separation was performed on a Symmetry ODS C18 (4.6×250mm, 5µm) column with Methanol: Phosphate Buffer (35:65) V/V as mobile phase at a flow rate of 1.0 mL min−1 with UV detection at 235 nm; the constant column temperature was Ambient. The run time under these chromatographic conditions was less than 8 min. The retention time of Apalutamide was found to be 2.252. The calibration plot was linear over the concentration range of 6–14 μg mL−1 with limits of detection and quantification values of 1.2 and 3.6 ng mL−1 respectively. The mean % assay of marketed formulation was found to be 99.86%, and % recovery was observed in the range of 98-102%. Relative standard deviation for the precision study was found <2%. The developed method is simple, precise, specific, accurate and rapid, making it suitable for estimation of Apalutamide in bulk and marketed pharmaceutical dosage form dosage form.